BioNTech’s Strategic Acquisition Nears Critical Deadline

The European biotech landscape is poised for a significant transformation as BioNTech approaches the final stages of its planned acquisition of CureVac. With shareholder approval secured, attention now shifts to the December 3, 2025 deadline that will determine whether this consolidation of German mRNA developers proceeds.

Overwhelming Shareholder Support Clears Path Forward

During Tuesday’s extraordinary general meeting, CureVac investors demonstrated near-unanimous backing for the proposed share exchange. An impressive 99.16 percent of voting shareholders approved the necessary resolutions, indicating strong investor confidence in combining these two pioneering mRNA technology firms.

Key transaction details include:

• Offer expiration: December 3, 2025, 3:00 PM CET
• Recommended submission deadline: December 2, 24:00 CET
• Exchange ratio: 0.05363 BioNTech ADS per CureVac share
• Minimum acceptance threshold: 80 percent of outstanding CureVac shares

Financial Strength Underpins Expansion Strategy

BioNTech enters this potential acquisition from a position of considerable financial power. The company’s third-quarter performance revealed revenues of €1.52 billion, substantially exceeding analyst projections of approximately €1.01 billion. This outperformance was largely driven by a $1.5 billion milestone payment from its collaboration with Bristol Myers Squibb.

Should investors sell immediately? Or is it worth buying BioNTech?

Although the company reported a quarterly loss of €0.12 per share, its balance sheet remains robust. With a current ratio exceeding 7, BioNTech maintains exceptional liquidity reserves, providing ample capacity to manage the CureVac integration without compromising operational stability.

Strategic Implications and Market Positioning

The proposed merger would strengthen BioNTech’s intellectual property portfolio within the mRNA sector while broadening its technological capabilities. Market experts have expressed varied but generally constructive assessments of the strategic move:

• H.C. Wainwright raised its price target to $140 with a “Buy” recommendation
• Clear Street identified $181 as a realistic valuation
• TD Cowen maintained a more cautious stance with a $116 target and “Hold” rating

BioNTech shares currently trade around the €95 level, showing stabilization after recent fluctuations. Market observers identify the December 3 acquisition conclusion as the next potential catalyst, contingent upon reaching the 80 percent acceptance threshold. Meanwhile, the stock faces headwinds from speculation about potential share sales by Pfizer and the company’s ongoing transition from COVID-19 specialization toward diversified oncology development.